Last update 08 May 2025

Kara Yakhteh Tajhiz Azma Company

Iran

Overview

Tags

Immune System Diseases
Hemic and Lymphatic Diseases
Neoplasms
CAR-T

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Immune System Diseases1
Hemic and Lymphatic Diseases1
Top 5 Drug TypeCount
CAR-T1
Top 5 TargetCount
CD19(B-lymphocyte antigen CD19)1

Related

1
Drugs associated with Kara Yakhteh Tajhiz Azma Company
Anti-CD19 CAR T cell(Kara Yakhteh Tajhiz Azma Company)
Target
CD19
Mechanism
CD19 modulators
Active Org.
Kara Yakhteh Tajhiz Azma Company
Originator Org.
Kara Yakhteh Tajhiz Azma Company
Active Indication
Pre B-cell acute lymphoblastic leukemia [+1]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Kara Yakhteh Tajhiz Azma Company
NCT06635330
/ RecruitingPhase 1/2IIT
A Phase I/II Single Arm Study, Safety and Efficacy Assessment of the CD19 CAR T Cell on Pediatric Patients with Relapsing or Refractory B Cell Acute Lymphoblastic Leukemia (r/r B-ALL)
100 Clinical Results associated with Kara Yakhteh Tajhiz Azma Company
Login to view more data
0 Patents (Medical) associated with Kara Yakhteh Tajhiz Azma Company
Login to view more data
100 Deals associated with Kara Yakhteh Tajhiz Azma Company
Login to view more data
100 Translational Medicine associated with Kara Yakhteh Tajhiz Azma Company
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Apr 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Anti-CD19 CAR T cell(Kara Yakhteh Tajhiz Azma Company)
 ( CD19 )		Refractory B Acute Lymphoblastic Leukemia
More
Phase 2 Clinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free